CHF91 -0.8 -0.9%
Last Trade - 10:50am
| Market Cap | £1.04bn |
| Enterprise Value | £1.00bn |
| Revenue | £53.0m |
| Position in Universe | 386th / 1045 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 60.6 | 67.7 | 67.2 | 65.6 | 62.5 | 60.9 | 60.9 | 73.9 | +0.1% | ||
| +31.3 | -78.1 | |||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Public Since | May 18, 2016 |
| No. of Shareholders: | n/a |
| No. of Employees: | 265 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | SIX Swiss Exchange |
| Shares in Issue | 14,433,300 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Riverside II Sir John Rogerson's Quay, DUBLIN, Ireland |
| Web | http://www.cosmopharma.com/ |
| Phone | +353 1 8170370 |
| Contact | Hans Tanner (Chief Financial Officer, Executive Director, Director of Investor Relations) |
| Auditors | BDO Audit & Assurance B.V |
As of 10:50am, shares in Cosmo Pharmaceuticals NV are trading at CHF91, giving the company a market capitalisation of £1.04bn. This share price information is delayed by 15 minutes.
Shares in Cosmo Pharmaceuticals NV are currently trading at CHF91 and the price has moved by 21.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cosmo Pharmaceuticals NV price has moved by -8.29% over the past year.
Of the analysts with advisory recommendations for Cosmo Pharmaceuticals NV, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cosmo Pharmaceuticals NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Cosmo Pharmaceuticals NV is scheduled to issue upcoming financial results on the following dates:
Cosmo Pharmaceuticals NV does not currently pay a dividend.
Cosmo Pharmaceuticals NV does not currently pay a dividend.
Cosmo Pharmaceuticals NV does not currently pay a dividend.
To buy shares in Cosmo Pharmaceuticals NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Cosmo Pharmaceuticals NV are currently trading at CHF91, giving the company a market capitalisation of £1.04bn.
Here are the trading details for Cosmo Pharmaceuticals NV:
Based on an overall assessment of its quality, value and momentum, Cosmo Pharmaceuticals NV is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Cosmo Pharmaceuticals NV are currently priced at CHF91. At that level they are trading at 20.34% discount to the analyst consensus target price of 0.00.
Analysts covering Cosmo Pharmaceuticals NV currently have a consensus Earnings Per Share (EPS) forecast of -0.911 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cosmo Pharmaceuticals NV. Over the past six months, the relative strength of its shares against the market has been -9.93%. At the current price of CHF91, shares in Cosmo Pharmaceuticals NV are trading at 7.22% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Cosmo Pharmaceuticals NV.
Cosmo Pharmaceuticals NV's management team is headed by:
Here are the top five shareholders of Cosmo Pharmaceuticals NV based on the size of their shareholding:
